About Prostate Cancer
Prostate cancer initiates in the prostate, which is an exocrine gland present in the male reproductive system. The main function of the prostate is to make fluid for semen. The risk of developing prostate cancer is age dependent. Prostate cancer affects mostly men over the age of 65 and rarely occurs in men younger than 40 years of age.
TechNavio's analysts forecast the Global Prostate Cancer Drugs market to grow at a CAGR of 10.45 percent over the period 2013-2018.
Covered in this Report
The Global Prostate Cancer Drugs market can be divided into four segments: Hormonal Therapy, Chemo Therapy, Immuno Therapy and Targeted Therapy. This report covers the present scenario and the growth prospects of the Global Prostate Cancer Drugs market for the period 2013–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the form of hormonal therapy, chemo therapy, immuno therapy, and targeted therapy for prostate cancer that are available in the market.
TechNavio's report, the Global Prostate Cancer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Prostate Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Abbvie
• Astra Zeneca
• Janssen Pharmaceuticals
• Sanofi
Other Prominent Vendors
• Amgen
• Astellas Pharma
• Bayer
• BMS
• Dendreon
• Endo Pharmaceuticals
• Ferring Pharmaceutical
• F. Hoffmann-La Roche
• GSK
• Ipsen
• Medivation
• Merck
• Novartis
• Pfizer
• Teva Pharmaceuticals
Market Driver
• Increase in Global Aging Population
• For a full, detailed list, view our report
Market Challenge
• High Cost of Prostate Cancer Drugs
• For a full, detailed list, view our report
Market Trend
• Major Opportunities for Pharmaceutical Companies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
08.1.1 US
08.1.2 Europe
09. Prostate Cancer Treatment Path
10. Prostate Cancer Treatment Options
11. Interpretation of Advanced Prostate Cancer
12. Current Landscape of Prostate Cancer Treatments
13. NCI Prostate Cancer Research Portfolio
14. Market Segmentation by Category
15. Geographical Segmentation
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and their Impact
23. Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2013
23.3 Other Prominent Vendors
24. Key Vendor Analysis
24.1 AbbVie Inc.
24.1.1 Key Facts
24.1.2 Business Overview
24.1.3 Product Segmentation by Revenue 2013
24.1.4 Product Segmentation by Revenue 2012 and 2013
24.1.5 Sales by Geography
24.1.6 Business Strategy
24.1.7 Key Developments
24.1.8 SWOT Analysis
24.2 AstraZeneca plc
24.2.1 Key Facts
24.2.2 Business Description
24.2.3 Business Segmentation
24.2.4 Business Strategy
24.2.5 Revenue by Business Segmentation
24.2.6 Revenue Comparison 2011-2013
24.2.7 Sales Revenue by Geographical Segmentation
24.2.8 Key Developments
24.2.9 SWOT Analysis
24.3 Janssen Pharmaceuticals
24.3.1 Key Facts
24.3.2 Business Overview
24.3.3 Recent Developments
24.3.4 SWOT Analysis
24.4 Sanofi
24.4.1 Key Facts
24.4.2 Business Description
24.4.3 Business Segmentation
24.4.4 Revenue by Business Segmentation
24.4.5 Revenue Comparison 2012 and 2013
24.4.6 Sales by Geography
24.4.7 Business Strategy
24.4.8 Key Developments
24.4.9 SWOT Analysis
25. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Prostate Cancer Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Clinical Trial Map of JNJ56021927/ARN-509
Exhibit 4: Clinical Trial Map of Zytiga
Exhibit 5: Clinical Trial Map of Docetaxel
Exhibit 6: Clinical Trial Map of Lapatinib Ditosylate
Exhibit 7: Clinical Trial Map of AZD5312
Exhibit 8: Rate of New Prostate Cancer Cases by Race and Ethnicity: US
Exhibit 9: Proportion of US Males with Prostate Cancer
Exhibit 10: Percentage of Total Dollars Contribution by Scientific Area in Fiscal Year 2012
Exhibit 11: Global Prostate Cancer Drugs Market Segmentation by Category
Exhibit 12: Global Prostate Cancer Drugs Market by Geographical Segmentation 2013
Exhibit 13: AstraZeneca Sales by Therapy Area 2013
Exhibit 14: J&J Market Sales by therapeutic Area (Pharmaceuticals) 2013
Exhibit 15: J&J Market Sales by Major Franchise (Medical Devices and Diagnostics) 2013
Exhibit 16: AbbVie Inc.: Product Segmentation by Revenue 2013
Exhibit 17: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18: AbbVie Inc.: Sales by Geography 2013
Exhibit 19: AstraZeneca: Business Segmentation
Exhibit 20: AstraZeneca: Revenue by Business Segmentation 2013
Exhibit 21: AstraZeneca: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 22: AstraZeneca: Sales Revenue by Geographical Segmentation 2013
Exhibit 23: Sanofi SA: Business Segmentation
Exhibit 24: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 25: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 26: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
